[International Human Rights] International Human Rights of Children || Children’s Right to Health
- 作者Kilkelly, Ursula; Liefaard, Ton
- 文件大小220.18KB
- 发表时间2018
- DOI10.1007/978-981-10-3182-3_12-1
- 页码1-22
Estimates of exceedances of critical loads for acidifying deposition in Alberta and SaskatchewanMakar, Paul A.; Akingunola, Ayodeji; Aherne, Julian; Cole, Amanda S.; Aklilu, Yayne-abeba; Zhang, Junhua; Wong, Isaac; Hayden, Katherine; Li, Shao-Meng; Kirk, Jane; Scott, Ken; Moran, Michael D.; Robichaud, Alain; Cathcart, Hazel; Baratzedah, Pegah; Pabla, Balbir; Cheung, Philip; Zheng, Qiong; Jeffries, Dean S. · Atmospheric Chemistry and Physics · 2018
Estimates of Exceedances of Critical Loads for Acidifying Deposition in Alberta and SaskatchewanMakar, Paul A.; Akingunola, Ayodeji; Aherne, Julian; Cole, Amanda S.; Aklilu, Yayne-abeba; Zhang, Junhua; Wong, Isaac; Hayden, Katherine; Li, Shao-Meng; Kirk, Jane; Scott, Ken; Moran, Michael D.; Robichaud, Alain; Cathcart, Hazel; Baratzedah, Pegah; Pabla, Balbir; Cheung, Philip; Zheng, Qiong; Jeffries, Dean S. · Atmospheric Chemistry and Physics Discussions · 2018
A human capecitabine excretion balance and pharmacokinetic study after administration of a single oral dose of 14C-labelled drugIan R. Judson; Philip J. Beale; José M. Trigo; Wynne Aherne; Thomas Crompton; David Jones; Ernie Bush; Bruno Reigner · 1999
Using solution thermodynamics to describe the dispersion of rod-like solutes: application to dispersions of carbon nanotubes in organic solventsMarguerite Hughes, J; Aherne, Damian; Bergin, Shane D; O’Neill, Arlene; Streich, Philip V; Hamilton, James P; Coleman, Jonathan N · Nanotechnology · 2012
PSMA-PET guided dose-escalated volumetric arc therapy (VMAT) for newly diagnosed lymph node positive prostate cancer: Efficacy and toxicity outcomes at two yearsShakespeare, Thomas Philip; Eggert, Elizabeth; Wood, Maree; Westhuyzen, Justin; Turnbull, Kirsty; Rutherford, Natalie; Aherne, Noel · Radiotherapy and Oncology · 2019
Multi-parameter lead optimization to give an oral checkpoint kinase 1 (CHK1) inhibitor clinical candidate: (R)-5-((4-((morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737).Osborne, James D; Matthews, Thomas Peter; McHardy, Tatiana; Proisy, Nicolas; Cheung, Kwai-Ming Jack; Lainchbury, Michael; Brown, Nathan; Walton, Michael I; Eve, Paul D; Boxall, Katherine J.; Hayes, Angela; Henley, Alan T; Valenti, Melanie R; De Haven Brandon, Alexis K; Box, Gary; Jamin, Yann; Robinson, Simon P; Westwood, Isaac M; van Montfort, Rob Leon Marie; Leonard, Philip M; Lamers, Marieke BAC; Reader, John C.; Aherne, G Wynne; Raynaud, Florence I; Eccles, Suzanne A.; Garrett, Michelle D; Collins, Ian · Journal of Medicinal Chemistry · 2016